Carfilzomib Effective, Tolerated as Replacement for Bortezomib in Multiple Myeloma

Share this content:

(CHICAGO, IL) – Carfilzomib is an effective and tolerable replacement for bortezomib for patients who are refractory to bortezomib-containing combination regimens for the treatment of multiple myeloma, according to the results of a Phase 1/2 study presented at the 2012 American Association of Clinical Oncology Annual Meeting.  

Data have shown multiple myeloma patients previously refractory to bortezomib-containing treatment regimens to be responsive to single-agent carfilzomib (CFZ), explained lead author James R. Berenson, MD, a medical oncologist in private practice in West Hollywood, CA. As a follow-up to these data, Berenson and his colleagues conducted a Phase 1/2 trial to investigate the safety and efficacy of carfilzomib as a replacement for bortezomib in a combination regimen for patients who progressed on, or within 12 weeks of receiving, that same combination regimen when containing bortezomib.

Twenty-seven patients were enrolled and 22 were evaluable and treated with CFZ and the following different combinations: bendamustine (BEND) alone; BEND + methylprednisolone; dexamethasone (DEX) alone; DEX + pegylated liposomal doxorubicin; ascorbic acid + cyclophosphamide; and melphalan alone. At the time of this presentation, patients had already completed a median of 6 cycles.

Clinical benefit was seen in 63.6% (n=14) patients (complete response=22.7%; very good partial response=4.5%; partial response=22.7%; minor response=13.6%) with another 27% (n=6) showing stable disease. The median time to progression and progression-free survival was 9.8 months. The most common grade 3/4 hematological adverse events were thrombocytopenia (59%) and lymphopenia (41%).

Investigators concluded that Carfilzomib is an effective and tolerable replacement for bortezomib for patients who are refractory to bortezomib-containing combination regimens for the treatment of multiple myeloma.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs